MindMed (NEO: MMED)
MindMed is a psychedelic medicine company with a primary focus on using formulations of Ibogaine and LSD to treat mental health issues. Their current pipeline features 18-MC (derived from Ibogaine) and LSD microdosing.
Cybin Corp (NEO: CYBN)
In October 2020 Cybin announced the closing of a $45 million raise, the largest funding round for a psychedelic company in Canadian history at the time. The company went public on the NEO exchange in November 2020.
Field Trip Health, Inc. (CSE: FTRP)
Field Trip is a mental wellness company that focuses on psychedelics and psychedelic-enhanced psychotherapy. In February 2020 they closed their Series A funding round, having raised $8.5m USD. The Company listed on the CSE on 6th Oct, 2020.
Revive Therapeutics Ltd. (CSE: RVV)
Revive has a primary focus on cannabinoid pharmaceuticals, but moved into the psychedelics space via the acquisition of Psilocin Pharma Corp. In December 2020, Revive announced an LOI to acquire PharmaTher’s psilocybin program, including all IP.
Numinus (TSXV: NUMI)
Numinus Wellness is a publicly-traded company that is licensed (via Salvation Botanicals) by Health Canada to test, sell and distribute psychedelic substances. It listed on the TSXV exchange on Wednesday 20th May, 2020.
HAVN Life Sciences (CSE: HAVN)
HAVN Life Sciences is a biotechnology company focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. They went public in September 2020.
Mydecine Innovations Group (CSE: MYCO)
Mydecine Innovations Group is a publicly traded life sciences syndicate. The Company’s portfolio includes natural health products, research and development, and digital health solutions.
Red Light Holland (CSE: TRIP)
Red Light Holland is seeking to capitalise on the existing recreational market in the Netherlands, selling magic truffles via Smart Shops and an e-commerce platform.
Champignon Brands Inc. (CSE: SHRM)
Champignon Brands is a publicly-traded, research-driven company active in the formulation and production of a variety of psychedelic medicines and products.
Entheon Biomedical (CSE: ENBI)
Entheon Biomedical is a biotech company focussed on the development of psychedelic medicines for addiction disorders. The Company’s research and development pipeline revolves around DMT.
Better Plant Sciences (CSE: PLNT)
The Company has a portfolio of over 100 psilocybin formulas via its subsidiary, Flourish Mushroom Labs. Flourish has formed a Company in Saint Vincent and the Grenadines, Acres Flourish Labs, which plans to construct a purpose-built laboratory for the cultivation of psilocybin mushrooms, and for R&D activities.
Tryp Therapeutics (CSE: TRYP)
Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
New Wave Holdings (CSE: SPOR)
New Wave is exploring recreational, natural (functional) and mental health applications of psychedelics. The company has two production facilities in Jamaica (via its 50% interest in Anahit International Corp.) licensed for mushroom cultivation, and is building a psilocybin-based IP portfolio.
Aion Therapeutic (CSE: AION)
Osoyoos is a company primarily associated with the cannabis space. In June 2020, the Company announced the proposed acquisition of AI Pharmaceuticals Jamaica Limited, who are engaged in the R&D of cannabis and psilocin-based pharmaceutical, nutraceutical and cosmeceutical formulations and related IP.
Lobe Sciences (CSE: LOBE)
Lobe Sciences – formerly GreenStar Biosciences – undertook a rebrand in November 2020 to shift toward the psychedelic medicine sector. The Company acquired Eleusian Biosciences, a psychedelic medicine development company.
PharmaTher (CSE: PHRM)
PharmaTher is a life sciences company focused on the R&D of psychedelics such as ketamine and psilocybin (and combinations with FDA-approved drugs) for the treatment of neurological disorders such as Parkinson’s disease, depression, and pain.
Hollister Biosciences (CSE: HOLL)
Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space.
Ehave Inc (OTC: EHVVF)
Ehave Inc provides digital therapeutics such as mental health informatics platforms. The company hopes to provide its services to the psychedelic medicine sector.
Mindset Pharma (CSE: MSET)
Mindset Pharma is a drug discovery and development company focused on developing next generation psychedelic medicines for neuropsychiatric and neurological indications with unmet needs.
M2BIO (OTC: WUHN)
M2BIO was formerly known as Wuhan General Group, changing their name in June 2020. The company is focused on cannabis and mushroom-based sciences and also offers consumer packaged goods.
Neonmind Biosciences (CSE: NEON)
NeonMind is hoping to harness psychedelics to tackle obesity, and has filed patent applications outlining the use of psilocybin for weight loss.
Roadman Investments Corp. (TSXV: LITT)
Roadman Investments Corp. is a Canadian Venture Capital and Advisory Firm. They have invested in a variety of companies in a range of sectors: from fintech to agriculture.
PsyBio Therapeutics (TSXV: PSYB)
PsyBio Therapeutics is exploring the production of biosynthesised psilocybin and other psychoactive molecules. The process involves the use of genetically modified bacteria (such as E. coli) as part of a patent-pending process.
Bright Minds Biosciences (CSE: DRUG)
Bright Minds Biosciences is focused on the preclinical study of targeted therapies “with the potential to improve the treatment of mental health and neurological disorders.” The company intends to develop next-generation neuropsychiatric drugs through the use of serotonergic compounds.
Silo Wellness (Coming Soon)
In June 2020, Silo Wellness announced a proposed RTO of Yukoterre Resources, meaning it may trade publicly soon.
Novamind (CSE: NM)
Novamind operates a network of retreats and clinics offering ketamine-assisted therapy. It also operates a contract research organisation, Cedar Clinical Research, which conducts clinical trials for psychedelic medicine.